Vaccinex
VCNX
Market cap $6.63M

2.55 USD

-0.27

9.57%

At close Oct 4, 4:00 PM EDT

After hours

2.48

-0.07

2.75%

1 day

-9.57%

5 days

-29.56%

1 month

-54.71%

3 months

-62.22%

6 months

-63.73%

Year to date

-75.83%

1 year

-83.44%

5 years

-99.81%

About: Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Employees: 40

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

7.28% less ownership

Funds ownership: 27.67% [Q1] → 20.39% (-7.28%) [Q2]

8% less funds holding

Funds holding: 12 [Q1] → 11 (-1) [Q2]

25% less capital invested

Capital invested by funds: $2.4M [Q1] → $1.81M (-$591K) [Q2]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VCNX.

See Analyst Rankings

Financial journalist opinion

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares.

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Vaccinex stock tanks 40% despite positive Alzheimer's study update

Vaccinex Inc (NASDAQ: VCNX) tanked an alarming 40% on Wednesday despite it reporting positive early-stage results for its Alzheimer's treatment. The biotechnology company said its SIGNAL-AD trial established its pepinemab antibody as well-tolerated by patients of AD.

Vaccinex stock tanks 40% despite positive Alzheimer's study update

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease in early June 2024. $8.2 million of new financing in Q1.

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant. The warrants will have an exercise price of $7.64 per share, will be immediately exercisable upon issuance and will expire 5 years from the initial exercise date. The registered direct offering and concurrent private placement are referred to herein as the “Transactions.”

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Vaccinex, Inc. Announces Reverse Stock Split

ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted basis.

Vaccinex, Inc. Announces Reverse Stock Split

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company's Board of Directors and the Company's Chief Executive Officer. The securities purchase agreement for the financing provides for the sale of an aggregate of 3,838,544 shares of the Company's common stock (and 1,265,078 common stock equivalents in lieu of common stock) together with common warrants to purchase up to an equal number (5,103,622) of shares of common stock. The shares and warrants are being sold at a combined purchase price per share and warrant of $0.725. The common warrants will have an exercise price of $1.00 per share. The common warrants will be immediately exercisable and will expire five years from the initial exercise date, provided, however, that the Company may call the warrants within 120 days after reporting specified positive topline data in the Company's ongoing SIGNAL-AD phase 1/2a clinical trial of its lead drug candidate, pepinemab, in Alzheimer's disease.

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

See News Rankings

Charts implemented using Lightweight Charts™